Overview

• The new facility in Houston’s Generation Park will produce active pharmaceutical ingredients for orforglipron and select oncology, immunology, cardiometabolic, and neuroscience therapies.
• Lilly says the site will create about 615 permanent high-wage roles and roughly 4,000 construction jobs in the Greater Houston area.
• Texas officials announced incentives, including an estimated $146 million through the state’s Jobs, Energy, Technology, and Innovation program and a $5.5 million Texas Enterprise Fund grant.
• The Houston plant is one of four new U.S. sites in Lilly’s at least $27 billion build-out, with two additional locations to be named this year and production across all four expected within five years.
• Orforglipron is an experimental once-daily oral GLP-1 that produced 12.4% average weight loss in a late-stage study, and Lilly plans to seek regulatory review later in 2025.